The Favourable Effects of Sodium-Glucose Cotransporter 2 inhibitors in Chronic Heart Failure Patients - The Fourth Pillar of Heart Failure Management

Background: The current global prevalence of heart failure is estimated at 64.34 million cases and 9.91 million years of disability as a result. Heart failure remains one of the most prevalent clinical syndromes associated with significant morbidity and mortality.